Home / Research library / Adipotide
Compound guide
Adipotide: what the research covers
Not a metabolic agent at all. It is a targeting peptide fused to a cell-killing sequence, designed to destroy the blood supply of fat tissue rather than to change how that tissue behaves.
What Adipotide is
Adipotide, also written FTPP for fat-targeted proapoptotic peptide, has two halves that do two different jobs. The first is a short motif that binds prohibitin, a protein found at unusually high levels on the endothelial cells lining the blood vessels of white adipose tissue. The second is a pro-apoptotic sequence, KLAKLAK repeated, which disrupts mitochondrial membranes once it is inside a cell.
Linked together, the construct is a targeting system: the first half finds the right cell type, the second half kills it. The intended consequence is loss of the capillary network supplying fat tissue, and subsequent regression of the tissue itself through lack of perfusion.
This is a fundamentally different mechanism from everything else in the metabolic group. Cagrilintide and the incretin agonists change signalling; AOD-9604 changes lipid handling within adipocytes; adipotide destroys vasculature.
Reading the evidence, and its stopping point
The published work is preclinical. Rodent and non-human primate studies reported substantial reductions in fat mass, and the primate data in particular is what made the compound well known. The mechanism was supported by the targeting experiments: constructs lacking the prohibitin motif did not produce the same effect.
The important part of the record is where it stops. Renal toxicity was observed in the primate work, which is unsurprising given that prohibitin is not exclusive to adipose endothelium and that an apoptosis-inducing payload has no built-in margin for error. Development did not proceed to the clinical use the early reports anticipated, and there is no human efficacy or safety literature.
A laboratory working with adipotide is working with a cytotoxic construct, and the honest framing of the compound is as a proof of concept for vascular targeting rather than as a metabolic agent. Any work with it should be designed around that, including the handling precautions appropriate to a pro-apoptotic sequence.
How Amino Club supplies it
Supplied lyophilised in sealed vials as Adipotide and released against the Certificate of Analysis for its own batch, as described on the lab testing page.
The KLAKLAK sequence is strongly cationic and amphipathic, which has two practical consequences: the peptide adsorbs readily to glass and ordinary plastic at low concentrations, and it is membrane active by design, so it should be treated as cytotoxic material in the laboratory rather than as an inert reference peptide. The sealed powder is stored below −18 °C and solutions prepared in small volumes immediately before use. Diluents are under reconstitution supplies.
Related reading
Adipotide is listed in the metabolic research peptides group with cagrilintide, mazdutide, survodutide, AOD-9604, 5-Amino-1MQ and AICAR, though its mechanism has nothing in common with any of them.
Every guide is indexed in the research library. Certificates and storage are covered on the FAQ, quantity pricing through bulk and wholesale.
Research use only
Adipotide supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.